ellipticine

04/09/2008 - "The viability results showed that the complexes with protonated ellipticine were effective in eradicating both cancer cells (viability <0.05), but their dilutions in water were not stable, leading to a fast decrease in their toxicity. "
11/03/2016 - "Cell viability assay results infer that EPT-MCM and EPT-MCM-Lyz showed much improved efficacy in HeLa cancer cells compared to free ellipticine."
04/29/2013 - "This study reports evidence of the toxicity of these novel compounds with overlapping structural and mechanistic similarities to ellipticine, a known anti-tumor compound."
01/15/2007 - "The study forms the basis to further predict the susceptibility of human cancers to ellipticine."
01/01/2006 - "The study forms the basis to further predict the susceptibility of human cancers to ellipticine."

01/01/2014 - "Effects of ellipticine on ALDH1A1-expressing breast cancer stem cells--an in vitro and in silico study."
12/01/2018 - "Ellipticine, was introduced in the treatment of metastatic breast cancer. "
07/19/2002 - "VIP-ellipticine derivatives inhibit the growth of breast cancer cells."
06/18/2013 - "An assay with the telomerase repeat amplification protocol shows that ellipticine inhibits telomerase activity in MDAMB-231 breast cancer cell line extracts. "
12/01/2005 - "Novel 1,3,9-triazacyclopenta[b]fluorene-4,10-diones and 1,3,9-triazacyclopenta[b]fluorene, analogue of ellipticine, were synthesised, and evaluated in vitro for their antiproliferative activity on various breast cancer cell lines."

07/18/2007 - "The results suggest the adduct formation as a new mode of antitumor action of ellipticine for leukemia."
07/01/1980 - "Formation of CHO cell colonies was inhibited by 50% following exposure to ellipticine for 2 hr at 6.0 microgram/ml or for 24 hr at 0.3 microgram/ml. Fifty % cell kill in asynchronously growing Friend leukemia and L1210 cells was obtained following exposure to ellipticine for 24 hr at 2.0 microgram/ml and 1.15 microgram/ml, respectively, whereas human peripheral blood lymphocytes required 66 hr exposure to 1.0 microgram/ml to kill 50% of the cells. "
11/03/1975 - "The antitumoral activity of two new derivatives of ellipticine, 9-hydroxy-2-methyl ellipticinium and 9-hydroxy-2,6-dimethyl-ellipticinium, has been determined using L 1210 mouse leukemia. "
12/01/2023 - "Subsequently, we tested both ellipticine and doxorubicin-loaded nanoparticles on a promyelocytic leukemia cell line, demonstrating efficient uptake by these cells and resulting in the expected cytotoxic effect."
01/01/2015 - "The results found in this work demonstrate similar cytotoxicity and DNA-damaging effects of ellipticine and its micellar form on leukemia HL-60 cells in vitro."

05/30/1981 - "[N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. "
02/01/2019 - "Ellipticine, a DNA-damaging drug, is another anticancer agent that is effective against certain tumors of the thyroid gland, ovarian carcinoma, breast cancer and osteolytic breast cancer metastasis. "

11/16/2023 - "The excellent cytotoxicity efficacy against the liver cancer cell line Hep-G2 was displayed by the 3,4-dichloro moiety containing indole-triazole scaffold 8b, which had the lowest cell viability (10.99 ± 0.59) compared with the standard drug ellipticine (cell viability = 11.5 ± 0.55) but displayed comparable potency in comparison with the standard drug doxorubicin (cell viability = 10.8 ± 0.41). "
03/22/1976 - "[Inhibitory effect of ellipticine (dimethyl-5,11-(6H) pyrido (4,3-b) carbazole on the induction of liver cancer by BT6 (N,N-dimethyl-p-(benzothiazolylazo) analine) and its effect on the levels of cytochrome P450 and arginase activity]."